Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological Approach

NVP-AAM077 was kindly provided by Dr. Yves Auberson (Novartis, Basel, Switzerland). We thank Philippe Ascher and Boris Barbour for comments on this manuscript. Over 20 years of pharmacological, physiological, and genetic studies have established that NMDA receptors (NMDARs), a subtype of ionotropic

[1]  D. Lovinger,et al.  Activation of NR2A-Containing NMDA Receptors Is Not Obligatory for NMDA Receptor-Dependent Long-Term Potentiation , 2005, The Journal of Neuroscience.

[2]  V. Pawlak,et al.  Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation , 2005, The Journal of Neuroscience.

[3]  M. Zhuo,et al.  Roles of NMDA receptor NR2A and NR2B subtypes for long‐term depression in the anterior cingulate cortex , 2005, The European journal of neuroscience.

[4]  P. Paoletti,et al.  Modulation of Triheteromeric NMDA Receptors by N-Terminal Domain Ligands , 2005, Neuron.

[5]  P. Paoletti,et al.  The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B , 2005, The Journal of Neuroscience.

[6]  S. Cull-Candy,et al.  Role of Distinct NMDA Receptor Subtypes at Central Synapses , 2004, Science's STKE.

[7]  Alastair M. Hosie,et al.  Zn2+ Ions: Modulators of Excitatory and Inhibitory Synaptic Activity , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[8]  G. Collingridge,et al.  Differential Roles of NR2A and NR2B-Containing NMDA Receptors in Cortical Long-Term Potentiation and Long-Term Depression , 2004, The Journal of Neuroscience.

[9]  M. Sheng,et al.  Role of NMDA Receptor Subtypes in Governing the Direction of Hippocampal Synaptic Plasticity , 2004, Science.

[10]  H. Tse,et al.  Structure–activity analysis of a novel NR2C/NR2D‐preferring NMDA receptor antagonist: 1‐(phenanthrene‐2‐carbonyl) piperazine‐2,3‐dicarboxylic acid , 2004, British journal of pharmacology.

[11]  John R Huguenard,et al.  Pathway-Specific Differences in Subunit Composition of Synaptic NMDA Receptors on Pyramidal Neurons in Neocortex , 2003, The Journal of Neuroscience.

[12]  P. Paoletti,et al.  Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors , 2002, The Journal of Neuroscience.

[13]  Y. Auberson,et al.  5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. , 2002, Bioorganic & medicinal chemistry letters.

[14]  Mark Farrant,et al.  NMDA receptor subunits: diversity, development and disease , 2001, Current Opinion in Neurobiology.

[15]  A. Fayyazuddin,et al.  Molecular Organization of a Zinc Binding N-Terminal Modulatory Domain in a NMDA Receptor Subunit , 2000, Neuron.

[16]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[17]  R. Dingledine,et al.  Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition , 1998, Nature Neuroscience.

[18]  S. Traynelis,et al.  Control of Voltage-independent Zinc Inhibition of Nmda Receptors by the Nr1 Subunit , 2022 .

[19]  P. Ascher,et al.  High-Affinity Zinc Inhibition of NMDA NR1–NR2A Receptors , 1997, The Journal of Neuroscience.

[20]  J. Kemp,et al.  A novel mechanism of activity‐dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. , 1996, The Journal of physiology.

[21]  J Kerby,et al.  Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. , 1995, Molecular pharmacology.

[22]  M. Mishina,et al.  Structure and function of the NMDA receptor channel , 1995, Neuropharmacology.

[23]  D. Laurie,et al.  Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. , 1994, European journal of pharmacology.

[24]  K Williams,et al.  Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. , 1993, Molecular pharmacology.

[25]  Matthew T. Geballe,et al.  Structure and Function of the NMDA Receptor , 2008 .